Vanda Pharmaceuticals Inc. (VNDA)

The total asset value of Vanda Pharmaceuticals Inc. (VNDA) stood at $ 738 Mln as on 31-Mar-23

The share price of Vanda Pharmaceuticals Inc. (VNDA) is $3.55 (NASDAQ) as of 28-Nov-2023 16:00 EST. Vanda Pharmaceuticals Inc. (VNDA) has given a return of -34.11% in the last 3 years.

Vanda Pharmaceuticals Inc. (VNDA) has a market capitalisation of $ 348 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Vanda Pharmaceuticals Inc. (VNDA) is 1.15 times as on 02-Jun-2023, a -0.55% premium to its peers’ median range of 2.54 times.

The P/E (price to earnings) ratio of Vanda Pharmaceuticals Inc. (VNDA) is 21.64 times as on 02-Jun-2023.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vanda Pharmaceuticals Inc. (VNDA) and enter the required number of quantities and click on buy to purchase the shares of Vanda Pharmaceuticals Inc. (VNDA).

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

The CEO & director of Dr. Mihael H. Polymeropoulos M.D.. is Vanda Pharmaceuticals Inc. (VNDA), and CFO & Sr. VP is Mr. Kevin Patrick Moran.

The promoters of Vanda Pharmaceuticals Inc. (VNDA) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

Yes, TTM profit after tax of Vanda Pharmaceuticals Inc. (VNDA) was $16 Mln.